留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

儿童肾移植受者的免疫抑制管理

赵闻雨, 朱有华. 儿童肾移植受者的免疫抑制管理[J]. 器官移植, 2022, 13(3): 283-287. doi: 10.3969/j.issn.1674-7445.2022.03.001
引用本文: 赵闻雨, 朱有华. 儿童肾移植受者的免疫抑制管理[J]. 器官移植, 2022, 13(3): 283-287. doi: 10.3969/j.issn.1674-7445.2022.03.001
Zhao Wenyu, Zhu Youhua. Immunosuppressive management in pediatric kidney transplant recipients[J]. ORGAN TRANSPLANTATION, 2022, 13(3): 283-287. doi: 10.3969/j.issn.1674-7445.2022.03.001
Citation: Zhao Wenyu, Zhu Youhua. Immunosuppressive management in pediatric kidney transplant recipients[J]. ORGAN TRANSPLANTATION, 2022, 13(3): 283-287. doi: 10.3969/j.issn.1674-7445.2022.03.001

儿童肾移植受者的免疫抑制管理

doi: 10.3969/j.issn.1674-7445.2022.03.001
基金项目: 

上海市卫生系统重要疾病联合攻关项目 2013ZYJB002

详细信息
    作者简介:
    通讯作者:

    朱有华, Email: zhuyouhua@126.com

  • 中图分类号: R617, R726.9

Immunosuppressive management in pediatric kidney transplant recipients

More Information
  • 摘要: 近年来,随着器官分配政策、外科手术技术及围手术期管理等方面的不断进步,儿童肾移植疗效逐渐提高,但免疫抑制管理对于儿童肾移植的长期预后仍十分重要。由于儿童在生理、心理、免疫系统和药物代谢等方面的特点不同于成人,其免疫抑制管理亦有特殊之处。因此,在实际临床工作中,需根据儿童肾移植受者的特点,有针对性地选择合适的免疫抑制剂并制定个体化的免疫抑制方案。本文从儿童肾移植受者免疫抑制治疗的特点、免疫抑制剂的选择、糖皮质激素减撤、免疫监测以及用药依从性管理等方面进行探讨,以期为优化儿童肾移植的免疫抑制管理,改善儿童肾移植受者的预后提供参考。

     

  • [1] VERGHESE PS. Pediatric kidney transplantation: a historical review[J]. Pediatr Res, 2017, 81(1/2): 259-264. DOI: 10.1038/pr.2016.207.
    [2] FERRARESSO M, TUROLO S, BELINGHERI M, et al. Relationship between mRNA expression levels of CYP3A4, CYP3A5 and SXR in peripheral mononuclear blood cells and aging in young kidney transplant recipients under tacrolimus treatment[J]. Pharmacogenomics, 2015, 16(5): 483-491. DOI: 10.2217/pgs.15.18.
    [3] ZONG YP, WANG ZJ, ZHOU WL, et al. Effects of CYP3A5 polymorphisms on tacrolimus pharmacokinetics in pediatric kidney transplantation: a systematic review and Meta-analysis of observational studies[J]. World J Pediatr, 2017, 13(5): 421-426. DOI: 10.1007/s12519-017-0035-4.
    [4] HART A, SMITH JM, SKEANS MA, et al. OPTN/SRTR 2018 annual data report: kidney[J]. Am J Transplant, 2020, 20(Suppl s1): 20-130. DOI: 10.1111/ajt.15672.
    [5] ASHOOR IF, MARTZ K, GALBIATI S, et al. Reassessing rabbit antithymocyte globulin induction in kidney transplantation (RETHINK): an analysis of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) Registry[J]. Transplant Direct, 2020, 6(9): e598. DOI: 10.1097/TXD.0000000000001042.
    [6] PULIYANDA DP, PIZZO H, RODIG N, et al. Early outcomes comparing induction with antithymocyte globulin vs alemtuzumab in two steroid-avoidance protocols in pediatric renal transplantation[J]. Pediatr Transplant, 2020, 24(3): e13685. DOI: 10.1111/petr.13685.
    [7] SHANG W, FENG G, GAO S, et al. Reduced ATG-F dosage for induction in pediatric renal transplantation: a single-center experience[J]. Pediatr Transplant, 2014, 18(3): 240-245. DOI: 10.1111/petr.12224.
    [8] ASHOOR IF, BEYL RA, GUPTA C, et al. Low-dose antithymocyte globulin has no disadvantages to standard higher dose in pediatric kidney transplant recipients: report from the pediatric nephrology research consortium[J]. Kidney Int Rep, 2021, 6(4): 995-1002. DOI: 10.1016/j.ekir.2021.01.007.
    [9] KAABAK MM, BABENKO NN, SHAPIRO R, et al. Eight-year follow-up in pediatric living donor kidney recipients receiving alemtuzumab induction[J]. Pediatr Transplant, 2017, 21(5): e12941. DOI: 10.1111/petr.12941.
    [10] MINCHAM CM, WONG G, TEIXEIRA-PINTO A, et al. Induction therapy, rejection, and graft outcomes in pediatric and adolescent kidney transplant recipients[J]. Transplantation, 2017, 101(9): 2146-2151. DOI: 10.1097/TP.0000000000001577.
    [11] ANDREWS LM, HESSELINK DA, VAN GELDER T, et al. A population pharmacokinetic model to predict the individual starting dose of tacrolimus following pediatric renal transplantation[J]. Clin Pharmacokinet, 2018, 57(4): 475-489. DOI: 10.1007/s40262-017-0567-8.
    [12] MALAKASIOTI G, BOOTH C, MARKS SD. Converting immunosuppression from an oral suspension to a granule formulation of tacrolimus in pediatric renal transplant recipients[J]. Pediatr Transplant, 2018, 22(5): e13214. DOI: 10.1111/petr.13214.
    [13] VONDRAK K, PARISI F, DHAWAN A, et al. Efficacy and safety of tacrolimus in de novo pediatric transplant recipients randomized to receive immediate- or prolonged-release tacrolimus[J]. Clin Transplant, 2019, 33(10): e13698. DOI: 10.1111/ctr.13698.
    [14] FUKUDA T, GOEBEL J, COX S, et al. UGT1A9, UGT2B7, and MRP2 genotypes can predict mycophenolic acid pharmacokinetic variability in pediatric kidney transplant recipients[J]. Ther Drug Monit, 2012, 34(6): 671-679. DOI: 10.1097/FTD.0b013e3182708f84.
    [15] AOKI Y, HAMASAKI Y, SATOH H, et al. Long-term outcomes of pediatric kidney transplantation: a single-center experience over the past 34 years in Japan[J]. Int J Urol, 2020, 27(2): 172-178. DOI: 10.1111/iju.14160.
    [16] PAPE L, AHLENSTIEL T. mTOR inhibitors in pediatric kidney transplantation[J]. Pediatr Nephrol, 2014, 29(7): 1119-1129. DOI: 10.1007/s00467-013-2505-9.
    [17] DUNMIRE SK, VERGHESE PS, BALFOUR HH JR. Primary Epstein-Barr virus infection[J]. J Clin Virol, 2018, 102: 84-92. DOI: 10.1016/j.jcv.2018.03.001.
    [18] WARD LM. Glucocorticoid-induced osteoporosis: why kids are different[J]. Front Endocrinol (Lausanne), 2020, 11: 576. DOI: 10.3389/fendo.2020.00576.
    [19] TÖNSHOFF B. Immunosuppressive therapy post-transplantation in children: what the clinician needs to know[J]. Expert Rev Clin Immunol, 2020, 16(2): 139-154. DOI: 10.1080/1744666X.2020.1714437.
    [20] BALANI SS, JENSEN CJ, KOURI AM, et al. Induction and maintenance immunosuppression in pediatric kidney transplantation-advances and controversies[J]. Pediatr Transplant, 2021, 25(7): e14077. DOI: 10.1111/petr.14077.
    [21] KUKLA A, CHEN E, SPONG R, et al. Recurrent glomerulonephritis under rapid discontinuation of steroids[J]. Transplantation, 2011, 91(12): 1386-1391. DOI: 10.1097/TP.0b013e31821bf157.
    [22] TÖNSHOFF B. Immunosuppressants in organ transplantation[J]. Handb Exp Pharmacol, 2020, 261: 441-469. DOI: 10.1007/164_2019_331.
    [23] LIVERMAN R, CHANDRAN MM, CROWTHER B. Considerations and controversies of pharmacologic management of the pediatric kidney transplant recipient[J]. Pharmacotherapy, 2021, 41(1): 77-102. DOI: 10.1002/phar.2483.
    [24] RESZTAK M, SOBIAK J, CZYRSKI A. Recent advances in therapeutic drug monitoring of voriconazole, mycophenolic acid, and vancomycin: a literature review of pediatric studies[J]. Pharmaceutics, 2021, 13(12): 1991. DOI: 10.3390/pharmaceutics13121991.
    [25] AHLENSTIEL-GRUNOW T, PAPE L. Novel ways to monitor immunosuppression in pediatric kidney transplant recipients-underlying concepts and emerging data[J]. Mol Cell Pediatr, 2021, 8(1): 8. DOI: 10.1186/s40348-021-00118-8.
    [26] HOEGY D, BLEYZAC N, ROBINSON P, et al. Medication adherence in pediatric transplantation and assessment methods: a systematic review[J]. Patient Prefer Adherence, 2019, 13: 705-719. DOI: 10.2147/PPA.S200209.
    [27] MEHTA P, STEINBERG EA, KELLY SL, et al. Medication adherence among adolescent solid-organ transplant recipients: a survey of healthcare providers[J]. Pediatr Transplant, 2017, 21(7): e13018. DOI: 10.1111/petr.13018.
    [28] CHISHOLM-BURNS MA, SPIVEY CA, REHFELD R, et al. Immunosuppressant therapy adherence and graft failure among pediatric renal transplant recipients[J]. Am J Transplant, 2009, 9(11): 2497-2504. DOI: 10.1111/j.1600-6143.2009.02793.x.
    [29] BOUCQUEMONT J, PAI ALH, DHARNIDHARKA VR, et al. Gender differences in medication adherence among adolescent and young adult kidney transplant recipients[J]. Transplantation, 2019, 103(4): 798-806. DOI: 10.1097/TP.0000000000002359.
    [30] NGUYEN C, DEW MA, IRIZARRY T, et al. Promoting medication adherence from the perspective of adolescent and young adult kidney transplant recipients, parents, and health care professionals: a TAKE-IT TOO study[J]. Pediatr Transplant, 2020, 24(5): e13709. DOI: 10.1111/petr.13709.
  • 加载中
图(1)
计量
  • 文章访问数:  681
  • HTML全文浏览量:  45
  • PDF下载量:  46
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-01-16
  • 网络出版日期:  2022-04-29
  • 刊出日期:  2022-05-15

目录

    /

    返回文章
    返回